Drug Profile
NYVAC-B
Alternative Names: HIV-1 vaccine NYVAC-B; NYVAC poxvirus vector + clade B gag-pol-nef + env immunogen; NYVAC-HIV-BLatest Information Update: 08 Apr 2022
Price :
$50
*
At a glance
- Originator EuroVacc Foundation; sanofi pasteur
- Developer EuroVacc Foundation
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections in Switzerland (IM, Injection)
- 29 Jan 2009 Phase-I development is ongoing